TransCelerate Biopharma
Active Since: 2012
Multi-Company Partnership
Contributing to SDGs…
TransCelerate is a nonprofit organization with the mission to collaborate across the biopharmaceutical industry to increase the efficiency, effectiveness and quality of the medicine development process.
MEMBER COMPANIES
-
AbbVie
Contribution
AbbVie is actively involved in TransCelerate at the leadership and member levels. Members of our clinical development teams have contributed over 1000 hours of work in the past year, across more than a dozen workstreams.
-
Amgen
-
Astellas Pharma Inc
-
AstraZeneca
-
Boehringer Ingelheim
-
Bristol-Myers Squibb
-
Eli Lilly and Company
-
F. Hoffmann – La Roche Ltd.
-
GlaxoSmithKline
-
Johnson & Johnson
-
Merck
-
MSD
-
Novo Nordisk
-
Pfizer Inc
-
Sanofi
Contribution
Sanofi is involved in several work streams: Patients & Sites, Sponsors & Drug Safety, Information Sharing & Harmonization, Sprint Projects (see link below). Jean Sposaro, Clinical Sciences & Operations Patient Network Management, was a fully seconded Sanofi employee to TransCelerate BioPharma for two years starting in 2017.
-
Shionogi & Co., Ltd.
-
UCB
PARTNER ORGANISATIONS
-
Global NGOs
TransCelerate
-
Professional and trade associations
ACRO CRO Forum
Contribution
The Forum provides an opportunity for subject matter experts (SMEs) from ACRO members and participating non-member companies to engage colleagues, provide industry input to TransCelerate workstreams and report back on TransCelerate developments, helping to inform member company perspectives and strategies
Objectives
- Accelerating and simplifying the drug development processes through collaboration.
The biopharmaceutical industry strives to ensure patient wellness and safety by producing new medicines that are safe and effective. However, the development of these medicines can be hampered by inefficiencies and challenges throughout the process of conducting clinical studies and applying for and receiving regulatory approval to make the medicine available to patients.
Through TransCelerate, participants in these processes collaboratively develop tools and procedures, clarify and harmonize standards and improve the patient experience so that clinical trials can occur more efficiently, results can be reported more accurately, regulatory reviews can be streamlined and patients around the world can have access to safe and effective medicines more quickly. TransCelerate has a portfolio of nearly 40 initiatives focused on specific aspects of these processes.
SDGs THE PARTNERSHIP CONTRIBUTES TO
SDG 3: Good Health and Wellbeing
SDG 9: Industry Innovation and Infrastructure
SDG 17: Partnerships for the Goals
RESULTS & MILESTONES
Since its founding in 2012, the TransCelerate partnership has developed and published multiple tools to aid in the efficient and effective development of new medicines. It has also developed shared knowledge bases on topics such as communication with clinical trial participants, investigator qualification and safety monitoring.
Geographic Reach
Global Commitment
Disease Area
Other
- General Health